Approval is based on 96-week data from 2 pivotal trials showing majority of EYLEA HD patients maintained their visual and anatomic improvements ...

Patients with diabetic macular edema can expect similar BCVA improvements and CST reductions using an aflibercept biosimilar compared with conventional aflibercept. An aflibercept biosimilar is ...

The FDA approved the first interchangeable biosimilars to aflibercept (Eylea) to treat macular degeneration, according to an announcement from the agency. As interchangeable biosimilars, ...

Credit: Getty Images. The BLA is supported by data from the pivotal PULSAR and PHOTON trials. The Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application ...

Brolucizumab (Beovu) proved noninferior to aflibercept (Eylea) for visual outcomes among patients with diabetic macular edema (DME), the phase III KINGFISHER trial showed. In over 500 patients with ...

Innovent Biologics’ eye disease prospect has matched Bayer and Regeneron’s Eylea in a phase 3 study, teeing up filings for ...

Please provide your email address to receive an email when new articles are posted on . Samsung Bioepis can launch Opuviz in the U.S. in January 2027. Opuviz, a biosimilar to Eylea, received FDA ...

Aflibercept is a vascular endothelial growth factor (VEGF) inhibitor first approved for treatment of diabetic macular edema (DME) in July 2014 after several large trials showed it was superior to ...

Please provide your email address to receive an email when new articles are posted on . A non-inferiority comparison between aflibercept and bevacizumab as first-line treatment for macular edema ...